Summary
20.58 -0.62(-2.92%)07/02/2024
Kura Oncology Inc (KURA)
Kura Oncology Inc (KURA)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
-2.81 | 0.44 | -2.74 | 0.39 | 33.98 | 94.15 | 2.44 | 37.20 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 20.58 | |
Open | 21.18 | |
High | 21.37 | |
Low | 20.48 | |
Volume | 412,626 | |
Change | -0.60 | |
Change % | -2.81 | |
Avg Volume (20 Days) | 407,823 | |
Volume/Avg Volume (20 Days) Ratio | 1.01 | |
52 Week Range | 7.41 - 24.16 | |
Price vs 52 Week High | -14.82% | |
Price vs 52 Week Low | 177.73% | |
Range | -2.83 | |
Gap Up/Down | -0.11 |
Fundamentals | ||
Market Capitalization (Mln) | 1,615 | |
EBIDTA | -63,452,000 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 36.71 | |
Book Value | 8.0260 | |
Earnings Per Share | -1.9230 | |
EPS Estimate Current Quarter | -0.5400 | |
EPS Estimate Next Quarter | -0.5700 | |
EPS Estimate Current Year | -2.0200 | |
EPS Estimate Next Year | -2.3400 | |
Diluted EPS (TTM) | -1.9230 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | 0.0000 | |
Return on asset (TTM) | -0.1729 | |
Return on equity (TTM) | -0.2949 | |
Revenue TTM | 0 | |
Revenue per share TTM | 0.0000 | |
Quarterly Revenue Growth (YOY) | 0.0000 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | 0 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 1.5238 | |
Revenue Enterprise Value | 0.0000 | |
EBITDA Enterprise Value | 0.0000 | |
Shares | ||
Shares Outstanding | 66,555,800 | |
Shares Float | 49,249,277 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.00 | |
Insider (%) | 2.94 | |
Institutions (%) | 105.13 |
06/24 07:30 EST - globenewswire.com
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes –
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes –
06/11 14:00 EST - businesswire.com
Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community
SAN DIEGO--(BUSINESS WIRE)--Life Science Cares San Diego, a nonprofit organization activating the financial and human capital of the life sciences industry and partnering with local nonprofits to disrupt the cycle of poverty and inequity throughout its communities, and Kura Oncology are continuing their partnership to support the San Diego community. Kura Oncology is contributing $100,000 through Life Science Cares' Basic Needs portfolio to support local nonprofit, Mama's Kitchen, with meeting.
Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community
SAN DIEGO--(BUSINESS WIRE)--Life Science Cares San Diego, a nonprofit organization activating the financial and human capital of the life sciences industry and partnering with local nonprofits to disrupt the cycle of poverty and inequity throughout its communities, and Kura Oncology are continuing their partnership to support the San Diego community. Kura Oncology is contributing $100,000 through Life Science Cares' Basic Needs portfolio to support local nonprofit, Mama's Kitchen, with meeting.
06/07 07:30 EST - globenewswire.com
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 3, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 152,500 shares of common stock to eight (8) new employees under the Company's 2023 Inducement Option Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 3, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 152,500 shares of common stock to eight (8) new employees under the Company's 2023 Inducement Option Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
05/29 07:30 EST - globenewswire.com
Kura Oncology to Participate in Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Jefferies Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on June 5, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event.
Kura Oncology to Participate in Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Jefferies Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on June 5, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event.
05/14 07:30 EST - globenewswire.com
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has completed enrollment of 85 patients in the Phase 2 portion of KOMET-001, a registration-directed clinical trial of the Company's menin inhibitor, ziftomenib (KO-539), in patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). The Company expects to report topline data from the trial in early 2025.
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has completed enrollment of 85 patients in the Phase 2 portion of KOMET-001, a registration-directed clinical trial of the Company's menin inhibitor, ziftomenib (KO-539), in patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). The Company expects to report topline data from the trial in early 2025.
05/08 08:30 EST - fool.com
2 Incredible Growth Stocks to Buy Hand Over Fist
Growth stocks are experiencing a multi-decade bull run at the moment. Kura Oncology and Hims & Hers are two red-hot growth stocks worth checking out right now.
2 Incredible Growth Stocks to Buy Hand Over Fist
Growth stocks are experiencing a multi-decade bull run at the moment. Kura Oncology and Hims & Hers are two red-hot growth stocks worth checking out right now.
05/08 07:30 EST - globenewswire.com
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2024 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 1:40 p.m. ET / 10:40 a.m. PT on May 15, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event.
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2024 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 1:40 p.m. ET / 10:40 a.m. PT on May 15, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event.
05/04 17:28 EST - seekingalpha.com
Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Pete De Spain - EVP, IR Troy Wilson - President & CEO Thomas Doyle - SVP of Finance & Accounting Conference Call Participants Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Roger Song - Jefferies Li Watsek - Cantor Fitzgerald Bradley Canino - Stifel Peter Lawson - Barclays Reni Benjamin - Citizens JMP Justin Zelin - BTIG George Farmer - Scotiabank Operator Good afternoon, ladies and gentlemen, and welcome to the Q1 2024 Kura Oncology Financial Results Conference Call. At this time, all participants are in listen-only mode.
Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Pete De Spain - EVP, IR Troy Wilson - President & CEO Thomas Doyle - SVP of Finance & Accounting Conference Call Participants Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Roger Song - Jefferies Li Watsek - Cantor Fitzgerald Bradley Canino - Stifel Peter Lawson - Barclays Reni Benjamin - Citizens JMP Justin Zelin - BTIG George Farmer - Scotiabank Operator Good afternoon, ladies and gentlemen, and welcome to the Q1 2024 Kura Oncology Financial Results Conference Call. At this time, all participants are in listen-only mode.
05/02 16:05 EST - globenewswire.com
Kura Oncology Reports First Quarter 2024 Financial Results
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma – – $527 million in cash, cash equivalents and investments provide runway into 2027 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2024 financial results and provided a corporate update.
Kura Oncology Reports First Quarter 2024 Financial Results
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma – – $527 million in cash, cash equivalents and investments provide runway into 2027 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2024 financial results and provided a corporate update.
04/25 07:30 EST - globenewswire.com
Kura Oncology to Report First Quarter 2024 Financial Results
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the close of U.S. financial markets on Thursday, May 2, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
Kura Oncology to Report First Quarter 2024 Financial Results
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the close of U.S. financial markets on Thursday, May 2, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
04/22 07:30 EST - globenewswire.com
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, ziftomenib, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). FDA granted BTD for ziftomenib based on data from Kura's ongoing KOMET-001 clinical trial in patients with R/R NPM1-mutant AML.
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, ziftomenib, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). FDA granted BTD for ziftomenib based on data from Kura's ongoing KOMET-001 clinical trial in patients with R/R NPM1-mutant AML.
04/10 07:30 EST - globenewswire.com
Kura Oncology to Participate in Stifel Targeted Oncology Forum
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2024 Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 11:30 a.m. ET / 8:30 a.m. PT on April 17, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event.
Kura Oncology to Participate in Stifel Targeted Oncology Forum
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2024 Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 11:30 a.m. ET / 8:30 a.m. PT on April 17, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event.
03/06 07:30 EST - globenewswire.com
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter –
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter –
02/27 16:01 EST - globenewswire.com
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome –
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome –
02/26 07:30 EST - globenewswire.com
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
– KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML –
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
– KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML –
02/22 07:30 EST - globenewswire.com
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:
02/20 07:30 EST - globenewswire.com
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.